Kodiak to Report DAYBREAK Phase 3 Data for Wet AMD Candidates on September 28
Kodiak Sciences will release topline results from the Phase 3 DAYBREAK trial on September 28, 2026. The study is evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-related macular degeneration. The company plans to host a webcast with the data.
Expanded Detail
EXPANDED:
Kodiak Sciences, a precommercial retina-focused company, intends to release DAYBREAK topline results on September 28, 2026. The Phase 3 trial assesses Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in wet age-related macular degeneration. A webcast is set for 8:30 a.m. Eastern that day, with a replay available briefly.
The company describes three late-stage programs. Zenkuda is
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Adicet Bio to Present Phase 1 Prula-cel Data in Lupus on September 28 · Drug development
Rezolute Reports Progress in Phase 3 Study for Rare Hypoglycemia Treatment · Drug development
Nanobiotix Reports Encouraging Early Data and Funding for Cancer Therapy · Cancer research
NeuroSense Advances ALS Therapy PrimeC Toward Canadian Filing · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration.” Browse more stories.